How many clinical trials have tested corticotropin?

Over 185 registered clinical trials have evaluated corticotropin across multiple indications. Most are completed, with results publicly available on ClinicalTrials.gov. This volume reflects its FDA-approved status and decades of clinical use.

What is corticotropin's evidence grade?

Corticotropin carries an A-grade evidence classification, the highest level of confidence. This is supported by multiple RCTs, consistent efficacy data, FDA regulatory approval, and 70+ years of clinical safety experience. Evidence grades vary by indication (A for infantile spasms, B for some autoimmune conditions).

What conditions does corticotropin have the strongest research for?

Infantile spasms (West syndrome) has the strongest evidence, with seizure cessation rates of 65-70% in clinical trials. Rheumatoid arthritis and lupus-related diseases have moderate evidence (B-grade). Off-label uses carry lower evidence grades pending further research.

Are there studies comparing corticotropin to newer treatments?

Few head-to-head trials compare corticotropin directly to modern biologics or immunosuppressants. Most research compares it to conventional glucocorticoids or placebo. This is a key research gap limiting clinical decision-making in current practice.

What are the main safety findings from 185+ trials?

Common side effects include hyperglycemia (10-15%), mood changes (5-8%), and hypertension (8-12%). Serious adverse events are rare (< 1%). Safety profile is consistent with systemic corticosteroid effects, though long-term safety data beyond 2 years remain limited.

Corticotropin Research Evidence: 185 Trials & Clinical Data

Corticotropin is an FDA-approved peptide hormone that stimulates cortisol production and has been studied extensively for over 70 years in clinical settings. With 185+ registered clinical trials, it ranks among the most researched peptide therapeutics. The compound carries an A-grade evidence classification, meaning robust clinical data supports its use in specific approved indications. Unlike newer peptides still in preclinical phases, corticotropin's research record includes decades of real-world clinical application, regulatory approval, and peer-reviewed validation. This deep-dive examines the clinical trial landscape, key studies, evidence grades, and where research gaps remain.

The Clinical Trial Landscape: 185+ Studies

Corticotropin has accumulated one of the most substantial clinical evidence bases of any peptide therapeutic. The ClinicalTrials.gov database lists 185 registered trials spanning multiple indications, study designs, and patient populations. This volume of investigation reflects both the compound's FDA-approved status and legitimate clinical questions about optimal dosing, formulations, and patient subgroups.

The trial portfolio breaks down across three major categories:

Active & Completed Trials

The majority of corticotropin trials are completed, with results published or available in clinical registries. Active recruitment trials tend to focus on emerging applications—such as newer formulations or pediatric indications—or real-world outcomes in specific patient populations. The breadth of trial participation spans academic medical centers, private practices, and pharmaceutical sponsors.

Study Designs & Rigor

Corticotropin's evidence base includes randomized controlled trials (RCTs), open-label studies, observational cohorts, and case series. A 2019 systematic review in the Journal of Clinical Medicine assessed trial quality and found that approximately 40% of registered trials employ RCT designs, which provide the highest level of evidence for efficacy claims. The remaining 60% are observational or open-label, useful for safety monitoring and real-world effectiveness assessment.

Key Research Findings: What the Evidence Shows

Primary Approved Indications

Corticotropin is FDA-approved for infantile spasms (West syndrome), a rare pediatric seizure disorder. The landmark trial demonstrating efficacy was published in 2004, showing that corticotropin injection produced seizure cessation in 65-70% of treated infants, compared to historical controls. This remains the gold-standard indication, with the most robust evidence grade.

The compound is also approved for select autoimmune and inflammatory conditions. A Cochrane systematic review on corticotropin for rheumatoid arthritis found moderate evidence that corticotropin may reduce joint inflammation and disease activity scores, though results varied by patient subgroup and dosing regimen.

Secondary & Off-Label Research Areas

Beyond FDA-labeled indications, clinical trials have explored corticotropin in:

Nephrotic syndrome: Multiple RCTs show corticotropin can reduce proteinuria in steroid-resistant cases, though efficacy depends on disease stage and glomerulonephritis type.
Polymyositis/dermatomyositis: Limited evidence; mostly case series and open-label trials.
Stroke recovery: Preclinical and early-phase human studies are ongoing, but no definitive efficacy data yet.

Mechanism Research

Recent mechanistic studies using positron emission tomography (PET) imaging reveal that corticotropin stimulates cortisol secretion via melanocortin receptor 2 (MC2R) activation on adrenal glands, which then modulates immune cell behavior and reduces inflammatory cytokine production. This mechanism differs from synthetic glucocorticoids, which act directly on glucocorticoid receptors; the finding opens questions about whether corticotropin-induced cortisol offers clinical advantages in certain inflammatory diseases.

Evidence Grades & Quality Assessment

A-Grade Evidence (Highest Confidence)

Corticotropin earns an A evidence grade for infantile spasms, based on:

Multiple RCTs with seizure cessation as primary endpoint
Consistent effect sizes across trials
FDA regulatory approval supported by clinical data
Long-term safety data spanning 20+ years of use

B-Grade Evidence (Moderate Confidence)

Evidence for rheumatoid arthritis and lupus-related conditions is B-grade:

Several RCTs and controlled observational studies exist
Effect sizes are moderate and variability between studies is notable
Publication bias may affect reported outcomes
Long-term follow-up data are limited

C-Grade Evidence (Lower Confidence)

Off-label uses (stroke, polymyositis, ulcerative colitis) carry C-grade evidence:

Mostly open-label trials, case reports, and small cohorts
Few head-to-head comparisons with standard-of-care treatments
Heterogeneous patient populations and outcome measures

Safety & Tolerability Profile

A 2017 pharmacovigilance analysis across 185 trials summarized adverse event data. Common side effects include:

Hyperglycemia (10-15% of patients)
Mood changes or psychiatric symptoms (5-8%)
Hypertension (8-12%)
Hypokalemia (3-6%)

Serious adverse events are rare (< 1%), but include adrenal insufficiency if abruptly discontinued and severe infections in immunocompromised patients. The safety profile is broadly consistent with systemic corticosteroid effects, though corticotropin's mechanism may confer a lower risk of certain adverse effects in specific populations—a hypothesis still under investigation.

Research Gaps & Unanswered Questions

Despite 185+ trials, significant gaps remain:

Comparative Effectiveness

Few head-to-head trials compare corticotropin directly to modern immunosuppressants or biologics (e.g., TNF inhibitors, JAK inhibitors). Most older trials compare corticotropin to conventional glucocorticoids or placebo, limiting guidance on which drug is preferred in current practice.

Long-Term Outcomes

Long-term follow-up data (beyond 2 years) are sparse. Questions persist about sustained remission rates, quality of life, and cumulative adverse effects over decades.

Biomarker Prediction

No validated biomarkers predict which patients will respond to corticotropin. Research into MC2R polymorphisms, baseline cortisol levels, or immune cell signatures could improve patient selection—but these studies are in early phases.

Pediatric Data

While infantile spasms data are robust, corticotropin use in other pediatric conditions (e.g., juvenile dermatomyositis) relies on small case series rather than RCTs.

Novel Formulations

Recent trials explore subcutaneous and extended-release formulations to improve convenience and adherence, but head-to-head efficacy comparisons are lacking.

Clinical Trial Registration & Transparency

Corticotropin trials are well-registered on ClinicalTrials.gov, with most results posted publicly. This transparency contrasts with some older compounds and reflects modern regulatory expectations. Researchers and clinicians can access trial designs, primary outcomes, and reported results, though peer-reviewed publications lag behind registration by 12-18 months on average.

How Corticotropin Fits the Broader Peptide Landscape

Corticotropin is one of the oldest peptide therapeutics—insulin and growth hormone are comparably mature—but differs from oxytocin or melanotan-II in that it has robust FDA approval and decades of clinical use. This maturity means research questions are now more nuanced: not whether it works (that's established), but for whom, in what dose, and compared to what alternative.

By contrast, BPC-157 and Thymosin Alpha-1 remain investigational with fewer trials and lower evidence grades, making direct comparisons of clinical utility premature.

The Bottom Line: What the Research Actually Shows

Corticotropin's evidence base is robust for specific, well-defined indications—particularly infantile spasms and select autoimmune diseases. The A-grade evidence reflects genuine clinical efficacy, not hype. However, the research also reveals that corticotropin is not a panacea: efficacy varies by disease, patient subgroup, and dosing strategy. Newer trials are exploring whether mechanistic differences between corticotropin and synthetic steroids offer clinical advantages in resistant cases.

The 185+ trials represent a mature, transparent evidence portfolio. Gaps remain around comparative effectiveness, long-term outcomes, and biomarker-guided selection, but these are questions for refinement, not fundamental proof-of-concept.

Corticotropin Research Evidence: What 185+ Clinical Trials Reveal